Enliven Therapeutics Inc [NASDAQ: ELVN] jumped around 0.09 points on Thursday, while shares priced at $20.73 at the close of the session, up 0.44%.
Enliven Therapeutics Inc stock is now -8.68% down from its year-to-date (YTD) trading value. ELVN Stock saw the intraday high of $21.335 and lowest of $20.27 per share. The company’s 52-week high price is 30.03, which means current price is +55.86% above from all time high which was touched on 01/03/25.
Compared to the average trading volume of 483.15K shares, ELVN reached a trading volume of 272510 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Enliven Therapeutics Inc [ELVN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ELVN shares is $40.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ELVN stock is a recommendation set at 1.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Enliven Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 16, 2025. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on December 13, 2024, representing the official price target for Enliven Therapeutics Inc stock. Previously, the target price had yet another raise to $37, while H.C. Wainwright analysts kept a Buy rating on ELVN stock.
The Price to Book ratio for the last quarter was 3.53, with the Price to Cash per share for the same quarter was set at 4.91.
How has ELVN stock performed recently?
Enliven Therapeutics Inc [ELVN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.67. With this latest performance, ELVN shares dropped by -5.17% in over the last four-week period, additionally sinking by -7.41% over the last 6 months – not to mention a drop of -7.87% in the past year of trading.
Enliven Therapeutics Inc [ELVN]: Deeper insight into the fundamentals
Return on Equity for this stock declined to -29.39%, with Return on Assets sitting at -29.39%.
Earnings analysis for Enliven Therapeutics Inc [ELVN]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ELVN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Enliven Therapeutics Inc go to -20.26%.
Insider trade positions for Enliven Therapeutics Inc [ELVN]
There are presently around $88.57%, or 92.98% of ELVN stock, in the hands of institutional investors. The top three institutional holders of ELVN stocks are: ORBIMED ADVISORS LLC with ownership of 7.96 million shares, which is approximately 16.5565%. FMR LLC, holding 5.69 million shares of the stock with an approximate value of $$133.08 million in ELVN stocks shares; and FMR LLC, currently with $$94.1 million in ELVN stock with ownership which is approximately 8.3751%.
